Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P78329

UPID:
CP4F2_HUMAN

ALTERNATIVE NAMES:
20-hydroxyeicosatetraenoic acid synthase; Arachidonic acid omega-hydroxylase; CYPIVF2; Cytochrome P450-LTB-omega; Docosahexaenoic acid omega-hydroxylase; Leukotriene-B(4) 20-monooxygenase 1; Leukotriene-B(4) omega-hydroxylase 1; Phylloquinone omega-hydroxylase CYP4F2

ALTERNATIVE UPACC:
P78329; A0A024R7K3; A8K425; B4DV75; Q16677; Q6NWT4; Q6NWT6; Q9NNZ0; Q9UIU8

BACKGROUND:
The Cytochrome P450 4F2 enzyme, with alternative names such as Arachidonic acid omega-hydroxylase and Phylloquinone omega-hydroxylase CYP4F2, plays a critical role in the oxidative metabolism of various substrates. It is involved in the conversion of arachidonic acid to vasoactive and natriuretic molecules, the inactivation of pro-inflammatory eicosanoids, and the metabolism of vitamins, thereby influencing vascular tone, inflammation, and nutrient utilization.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Cytochrome P450 4F2 could open doors to potential therapeutic strategies. Its involvement in Coumarin resistance, through the variant Met-433, presents a direct link to challenges in managing thromboembolic diseases with warfarin. This connection offers a pathway for developing more effective anticoagulant therapies by targeting specific enzyme variants.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.